KR20090109587A - 녹내장 또는 고안압 처리를 위한 감마-락탐 - Google Patents

녹내장 또는 고안압 처리를 위한 감마-락탐 Download PDF

Info

Publication number
KR20090109587A
KR20090109587A KR1020097018979A KR20097018979A KR20090109587A KR 20090109587 A KR20090109587 A KR 20090109587A KR 1020097018979 A KR1020097018979 A KR 1020097018979A KR 20097018979 A KR20097018979 A KR 20097018979A KR 20090109587 A KR20090109587 A KR 20090109587A
Authority
KR
South Korea
Prior art keywords
substituted
another embodiment
phenyl
compound
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097018979A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 더블유. 올드
화 빈 임
빈 엑스. 엔고
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20090109587A publication Critical patent/KR20090109587A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/2672-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097018979A 2007-02-15 2008-02-08 녹내장 또는 고안압 처리를 위한 감마-락탐 Ceased KR20090109587A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89018107P 2007-02-15 2007-02-15
US60/890,181 2007-02-15
PCT/US2008/053386 WO2008100809A1 (en) 2007-02-15 2008-02-08 Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure

Publications (1)

Publication Number Publication Date
KR20090109587A true KR20090109587A (ko) 2009-10-20

Family

ID=39511007

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018979A Ceased KR20090109587A (ko) 2007-02-15 2008-02-08 녹내장 또는 고안압 처리를 위한 감마-락탐

Country Status (12)

Country Link
US (1) US8362054B2 (https=)
EP (1) EP2118094B1 (https=)
JP (1) JP5566696B2 (https=)
KR (1) KR20090109587A (https=)
CN (1) CN101657445B (https=)
AU (1) AU2008216499B2 (https=)
BR (1) BRPI0807600A2 (https=)
CA (1) CA2678191A1 (https=)
ES (1) ES2404169T3 (https=)
MX (1) MX2009008734A (https=)
NZ (1) NZ598945A (https=)
WO (1) WO2008100809A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055289A2 (en) * 2007-10-23 2009-04-30 Allergan, Inc. Therapeutic substituted lactams
CN117500791A (zh) * 2021-03-08 2024-02-02 阿比奥尼克斯制药公司 可用于治疗肝脏疾病的化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
KR100437972B1 (ko) * 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
JP4754820B2 (ja) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
JP2008538547A (ja) 2005-03-09 2008-10-30 ロジャー・ウィリアムズ・ホスピタル 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法
CA2599425C (en) * 2005-03-10 2013-04-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists

Also Published As

Publication number Publication date
JP5566696B2 (ja) 2014-08-06
MX2009008734A (es) 2009-08-25
CN101657445B (zh) 2013-06-05
EP2118094A1 (en) 2009-11-18
AU2008216499B2 (en) 2014-04-17
AU2008216499A1 (en) 2008-08-21
ES2404169T3 (es) 2013-05-24
WO2008100809A1 (en) 2008-08-21
NZ598945A (en) 2013-08-30
CN101657445A (zh) 2010-02-24
CA2678191A1 (en) 2008-08-21
US8362054B2 (en) 2013-01-29
JP2010519208A (ja) 2010-06-03
BRPI0807600A2 (pt) 2014-07-22
US20100168189A1 (en) 2010-07-01
EP2118094B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
US8722726B2 (en) Substituted arylcyclopentenes as therapeutic agents
AU2007249443B2 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
US7960381B2 (en) Substituted gamma lactams as therapeutic agents
US7795287B2 (en) Therapeutic substituted hydantoins and related compounds
EP2029518A2 (en) Cyclopentane-derivatives and their use as ocular hypotensive agents
KR20090109587A (ko) 녹내장 또는 고안압 처리를 위한 감마-락탐
EP2019820B1 (en) Therapeutic pyrrolidine compounds
US7498447B2 (en) Therapeutic compounds
US7659295B2 (en) Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
US9796696B2 (en) Substituted arylcyclopentenes as therapeutic agents
US8440819B2 (en) Therapeutic substituted beta-lactams
EP2049495A2 (en) N-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives as prostaglandine receptor inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130122

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I